Skip to main content
. 2016 Sep 29;68(11):2584–2592. doi: 10.1002/art.39751

Figure 1.

Figure 1

A, Mean synovial vascularity score for metacarpophalangeal joint 2 (MCP2), MCP3, MCP5, metatarsophalangeal joint 5 (MTP5), and the wrist in patients with rheumatoid arthritis at baseline and at weeks 4, 8, 12, 16, 20, and 24 of treatment with adalimumab plus methotrexate. B, Percentage of total change at each joint from baseline to week 24 accounted for by change in dorsal and volar views. C, Percentage of joints with a synovial vascularity score of ≥2 at baseline and week 24. Bilateral dorsal (dorsal left [Dor‐L] and dorsal right) and volar (volar left [Vol‐L] and volar right) scoring was performed for MCP2, MCP3, and MCP5; only dorsal scoring was performed for MTP5 and the wrist. Scores are from the primary reader. Analysis was based on as‐observed cases. ∗ = P < 0.05; ∗∗ = P < 0.01; ∗∗∗ = P < 0.001 versus week 24, by chi‐square test. D, Percentage of patients with a synovial vascularity score of ≤1 at baseline and week 24. ∗ = P < 0.05 by chi‐square test.